Washington: Johnson & Johnson has begun a last-stage trial of a coronavirus vaccine that will require only one dose. Most vaccines that are being developed require two doses. The company plans to test the vaccine on 60,000 volunteers, which is the largest number so far, starting in this study on Wednesday. Apart from the US, these trials are taking place in South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru.
Experts say that even if the company’s vaccine lags behind other candidates, it can have other benefits. The biggest advantage is that there is no need to store it in subzero temperature. Immunity can develop by giving not one, but only one dose. The company’s Chief Scientific Officer, Dr Paul Stauffle, says that by the end of the year, it can be confirmed how safe and effective the vaccine is.
This is how the vaccine works
This vaccine carries the gene of coronavirus spike protein in adenovirus to the human body. At the same time, West Virginia University Vice-Chairwoman Doy Judith Feinberg says that only after the Phase III trial will it be clear if one of its doses is effective. If this happens, it may make it easier to control the epidemic.